Agonists

Product #

Image

Description

Biochem/physiol Actions

Add to Cart
P4532 (−)-N6-(2-Phenylisopropyl)adenosine solid A1 adenosine receptor agonist. Affinity for adenosine receptor is approx. 100× that of the (+)-isomer.
    • E111   (S)-ENBA Selective A1 adenosine receptor agonist.
    • M152 2-(Methylthio)adenosine 5′-diphosphate trisodium salt hydrate ≥89% (HPLC), solid 2-Methylthio-ADP (2-ME-SADP) is a P2 purinoceptor agonist, which induces platelet aggregation and shape change and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1. Compared with ADP, 2-methylthio-ADP was 3-5 times as active as an aggregating agent and 150-200 times as active as an inhibitor of cyclic AMP accumulation. Purinergic signaling may be an important factor in TSP-1-mediated cell-matrix and cell-cell interactions such as those occurring during development and repair.
    • A023 2-(Methylthio)adenosine 5′-triphosphate tetrasodium salt hydrate solid, ≥90% 2-Methylthioadenosine triphosphate is a potent P2Y purinoceptor agonist.
    • P101 2-Phenylaminoadenosine >97%, solid Selective A2 adenosine receptor agonist; potent coronary vasodilator; weak inhibitor of adenosine uptake by rat cerebral cortical synaptosomes.
    • C5134 2-Chloroadenosine Selective A1 adenosine receptor agonist.
    • E2387 5′-(N-Ethylcarboxamido)adenosine powder Potent adenosine receptor agonist with nearly equal affinity at A1 and A2 receptors.
    • B3756 8-Bromoadenosine 5′-triphosphate sodium salt ≥90% (HPLC) P2X purinoceptor agonist similar in reactivity to ATP.
    • A236 AB-MECA solid High affinity A3 adenosine receptor agonist.
    • A8016 Adenosine 5′-[β-thio]diphosphate trilithium salt ≥80% (HPLC) P2Y receptor agonist.
    • A5285 Adenosine 5′-diphosphate monopotassium salt dihydrate bacterial, ≥95%, crystalline P2Y receptor agonist.
    • A7699 Adenosine 5′-triphosphate disodium salt hydrate BioXtra, ≥99%, from microbial P2 purinergic agonist; increases activity of Ca2+-activated K+ channels; substrate for ATP-dependent enzyme systems
    • A111 Adenosine amine congener hydrate solid, ≥98% (HPLC) Potent aqueous-soluble A1 adenosine receptor agonist.
    • A9251 Adenosine ≥99% Endogenous neurotransmitter at adenosine receptors. Cardioprotective effects may relate to activation of A1 adenosine receptors. The antiplatelet and anti−inflammatory actions of adenosine appear to be mediated via the A2 adenosine receptor. In contrast, adenosine appears to be a pro-inflammatory mediator in asthma and chronic obstructive pulmonary disease (COPD).
    • C141 CGS-21680 hydrochloride hydrate solid Adenosine receptor agonist, which possesses selectivity for A2 verses A1 receptors.
    • C277 Chloro-IB-MECA solid, ≥98% (HPLC) A3 adenosine receptor agonist.
    • C1506 Cytidine 5′-triphosphate disodium salt ≥95% P2X4 purinergic receptor agonist.
    • C9274 Cytidine 5′-triphosphate disodium salt ~95% P2X4 purinergic receptor agonist.
    • G5794 GR 79236X ≥99% (HPLC), solid A1 adenosine receptor agonist
    • H3288 HEMADO ≥99% (HPLC), solid A3 adenosine receptor agonist
    • I146 IB-MECA solid, ≥98% (HPLC) Selective A3 adenosine receptor agonist.
    • K3769 KW-3902 ≥98% (HPLC) KW-3902 is an A1 adenosine receptor antagonist and is over 800 fold more selective for an A1 receptor versus the A2A receptor.
    • P2673 N6-(2-Phenylethyl)adenosine Selective A1 adenosine receptor agonist.
    • A202 N6-2-(4-Aminophenyl)ethyladenosine >95% Potent, non-selective A3 adenosine receptor agonist.
    • B152 N6-Benzyl-5′-N-ethylcarboxamidoadenosine solid Selective A3 adenosine receptor agonist.
    • C9901 N6-Cyclohexyladenosine Selective A1 adenosine receptor agonist.
    • C8031 N6-Cyclopentyladenosine solid Selective A1 adenosine receptor agonist.
    • S198   N6-p-Sulfophenyladenosine sodium salt solid A1 adenosine receptor agonist.
    • P1123 PD 81,723 ≥98% (HPLC), solid Allosteric enhancer of A1 adenosine receptors
    • U4125 Uridine 5′-(trihydrogen diphosphate) sodium salt from Saccharomyces cerevisiae 95-100% P2Y receptor agonist.
    • U6875 Uridine 5′-triphosphate tris salt Type VI, ≥90% P2Y receptor agonist.
    • U6750 Uridine 5′-triphosphate trisodium salt hydrate Type IV, 90-95% P2Y receptor agonist.
    • U6625 Uridine 5′-triphosphate trisodium salt hydrate from yeast, Type III, ≥96% P2Y receptor agonist.
    • M6517 α,β-Methyleneadenosine 5′-triphosphate lithium salt ≥93% (HPLC), solid P2 purinoceptor agonist that is more potent than ATP at the P2X subtype.
    • M7510 β,γ-Methyleneadenosine 5′-triphosphate disodium salt ≥95%, solid Selective P2X purinoceptor agonist that is more potent than ATP, but less potent than α, β-methylene-L-adenosine 5′-triphosphate.